Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2007-06-12
2007-06-12
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S278000, C514S306000, C540S459000
Reexamination Certificate
active
11186187
ABSTRACT:
Novel rifamycin derivatives of formula I (both hydroquinone and corresponding quinone (C1-C4) forms):or their salts, hydrates or prodrugs thereof,wherein: a preferred R comprises hydrogen, acetyl; L is a linker, a preferred linker group elements selected from any combination of 1 to 5 groups shown FIG.1, provided L is notwherein R1is H, methyl or alkyl. The inventive compounds exhibit valuable antibiotic properties. Formulations having these compounds can be used in the control or prevention of infectious diseases in mammals, both humans and non-humans. In particular, the compounds exhibit a pronounced antibacterial activity, even against multiresistant strains of microbes.
REFERENCES:
patent: 5786350 (1998-07-01), Occelli et al.
patent: WO 94/28002 (1994-12-01), None
patent: WO 03/045319 (2003-06-01), None
patent: WO 2005/070940 (2005-08-01), None
patent: WO 2005/070941 (2005-08-01), None
Farr, BM. Rifamycins, in Principles and Practice of Infectious Diseases. Mandell GL, Bennett JE, Dolin R, Eds. Churchhill Livingstone Philadelphia pp. 348-361.
Li Q, Chu DT, Claiborne, A, Cooper CS, Lee CM, Raye K, Berst KB, Donner P, Wang W, Hasvold L, Fung A, Ma Z, Tufano M, Flamm R, Shen LL, Baranowski J, Nilius A, Alder J, Meulbroek J, Marsh K, Crowell D, Hui Y, Seif L, Melcher LM, Plattner JJ, et al. Synthesis and structure-activity relationships of 2-pyridones: a novel series of potent DNA gyrase inhibitors as antibacterial agents. J Med Chem. Aug. 2, 1996;39(16):3070-88.
Li Q, Mitscher LA, Shen LL. The 2-pyridone antibacterial agents: bacterial topoisomerase inhibitors. Med Res Rev. Jun. 2000;20(4):231-93.
Marsili L, Pasqualucci CR, Vigevani A, Gioia B, Schioppacassi G, Oronzo G. New rifamycins modified at positions 3 and 4. Synthesis, structure and biological evaluation. J Antibiol (Tokyo). Aug. 1981;34(8):1033-8.
Yamane T, Hashizume T, Yamashita K, Konishi E, Hosoe K, Hidaka T, Watanabe K, Kawaharada H, Yamamoto T, Kuze F. Synthesis and biological activity of 3′-hydroxy-5′-aminobenzoxazinorifamycin derivatives. Chem Pharm Bull (Tokyo). Jan. 1993;41(1):148-55.
PCT Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration. Dec. 6, 2005.
Combrink Keith D.
Ding Charles Z.
Harran Susan
He Yong
Jin Yafei
Cumbre Pharmaceuticals Inc.
Jackson Walker L.L.P.
Kifle Bruck
LandOfFree
Rifamycin derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Rifamycin derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Rifamycin derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3823155